Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?

Refining the classification criteria for primary Sjögren syndrome

(2017) Arjan Vissink et al.   Nature Reviews Rheumatology

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

(2017) Simon J. Bowman et al.   Arthritis & Rheumatology

Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment

(2016) Konstantina Delli et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies

(2016) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of treatments for primary Sjögren’s syndrome

(2016) Jolien F. van Nimwegen et al.   Expert Opinion On Drug Safety

B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome

(2016) Gwenny M. Verstappen et al.   JOURNAL OF RHEUMATOLOGY

2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts

(2016) Caroline H. Shiboski et al.   Arthritis & Rheumatology

High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren’s Syndrome: Data from the TEARS Randomized Trial

(2016) Divi Cornec et al.   PLoS One

Development of the Sjögren’s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy

(2015) Divi Cornec et al.   RHEUMATOLOGY

Treatment of Primary Sjögren Syndrome With Rituximab

(2014) Valérie Devauchelle-Pensec et al.   ANNALS OF INTERNAL MEDICINE

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

(2014) P M Meiners et al.   ANNALS OF THE RHEUMATIC DISEASES

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

(2014) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

B-cell hyperactivity in primary Sjögren's syndrome

(2014) Frans GM Kroese et al.   Expert Review of Clinical Immunology

EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

(2013) R V Moerman et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab Therapy for Primary Sjögren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis

(2013) E. William St.Clair et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

(2013) Francesco Carubbi et al.   ARTHRITIS RESEARCH & THERAPY

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

(2011) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren’s Syndrome: A Retrospective Clinical Study

(2011) RODNEY P.E. POLLARD et al.   JOURNAL OF RHEUMATOLOGY

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

(2009) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome

(2009) J. Pijpe et al.   ARTHRITIS AND RHEUMATISM